

EGM update and advance of funds

Australian-based reproductive biotechnology company, Memphasys Limited (ASX: MEM) advise that at the company's general meeting held on 14 February 2024, shareholders approved, amongst other resolutions, the issue of ordinary shares and options (securities) to Mr Andrew Goodall, a related party of the company, subject to Mr Goodall remitting \$150,058.82 to the company to complete an application of the securities.

Mr Goodall was unable to complete the application within the timeframe approved by shareholders in accordance with the ASX listing rules and the securities can therefore not be issued pursuant to that resolution.

Mr Goodall has offered to advance the amount equal to the subscription, being \$150,058.82 by 22 March 2024, as an advance pending approval of the issue of the shares and options the subject of the original shareholders resolution at the next General Meeting of shareholders.

The Board thanks Mr Goodall for his continued support of the Company.

This announcement has been approved for release by the board of Memphasys Limited.

ENDS

For further information, please contact:

Dr David Ali
Acting Managing Director / Chief Executive Officer
Memphasys Limited
Tel: +61 2 8415 7300
E: david.ali@memphasys.com

David Tasker
Managing Director
Chapter One Advisors
Tel: +61 433 112 936
E: dtasker@chapteroneadvisors.com.au

About Memphasys

Memphasys Limited (ASX: MEM) specialises in reproductive biotechnology for high value commercial applications. Reproductive biotechnology products in development include medical devices, *in vitro* diagnostics, and new proprietary media. The Company's patented bio-separation technology, utilised by the Company's most advanced product, the Felix™ System device, combines electrophoresis with proprietary size exclusion membranes to separate the most viable sperm cells for human artificial reproduction.

Website: www.memphasys.com

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.